AbbVie (ABBV) announced it received a Complete Response Letter from the FDA regarding the Biologics License Application for trenibotulinumtoxinE, a botulinum neurotoxin serotype E with a rapid onset of effect and short duration. The FDA requested additional information about manufacturing processes.
The company noted that the CRL does not identify any safety or efficacy concerns for TrenibotE, and does not request additional clinical studies. AbbVie expects to submit a thorough response in the coming months.
At last close, AbbVie shares were trading at $200.95, up 0.22%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.